GoodRx Holdings heads into its Q1 2026 earnings print on May 7 with short sellers piling in at a pace not seen in months — even as the stock itself has quietly rallied 10% this week.
The tension is stark. Short interest jumped 59% in a single week, climbing from roughly 8.5% to 13.6% of the free float. That is the highest level in the 30-day window tracked here, and the move came almost entirely in the last two sessions — May 4 and May 5 — suggesting fresh conviction bets rather than a gradual drift. The ORTEX short score reached 71.3 on May 5, up sharply from 56 just four days earlier. Availability has also tightened considerably: the lending pool moved to its tightest reading of the past year at 66% availability, reflecting how quickly those new borrow positions have been established. Cost to borrow remains modest at 0.75% annualised — no squeeze pressure yet, and the borrow is still cheap — but the combination of surging short interest and tightening availability is a notable shift in the setup.
Options traders are not amplifying the caution. The put/call ratio is 0.21, almost exactly in line with its 20-day average of 0.21, and a z-score near zero signals no unusual positioning in either direction. The 52-week range on the PCR runs from 0.07 to 0.32, and the current reading barely registers on that spectrum. This is a call-heavy book — not a defensive one. That is a meaningful divergence from the short-interest surge: equity borrowers are bracing, options traders are not.
The analyst backdrop has been uniformly negative since February and is now borderline stale at 64 days old. Following a painful earnings miss in late February — the stock fell 24% in a day and another 7% in the subsequent week — Wells Fargo, Citi, Goldman, Mizuho and JPMorgan all cut targets or ratings within days of the print. Goldman moved to Neutral at $2.50; JPMorgan downgraded to Neutral outright. Most remaining targets from that cohort cluster in the $3.00–$3.50 range, above the current $2.56 price. The mean consensus target of $2.97 implies limited upside by recent Street standards. On valuation, the stock trades at an EV/EBITDA of around 4.8x — not demanding — and the P/E ratio has risen 22% over the past 30 days purely on price appreciation, now at roughly 7.6x. The EV/EBIT factor ranks in the 77th percentile, which suggests the market is ascribing some credit for the operating earnings base even as the growth story remains contested.
The earnings history adds the sharpest context. The February 2026 print triggered the 24% single-day decline. The one before it — in March 2026 — produced a 10.7% gain on the day and a 26% five-day move higher. The pattern is binary and volatile. In both directions. The surge in short interest this week looks less like a structural view on GoodRx and more like a directional bet ahead of a known catalyst — traders are paying for a position, not a thesis. Close peers TDOC and LFMD both gained around 11–13% on the week, suggesting health-care tech sentiment broadly is constructive, which makes the short build on GDRX even more targeted.
The May 7 report is the next event that will resolve this. Given the sharpness of the recent short build and the historical volatility of the stock's own earnings reactions, the size of any move — not the direction — is the number to watch.
See the live data behind this article on ORTEX.
Open GDRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
